GH Research’s Mebufotenin (5-MeO-DMT) and its Salt Products Receive European Patent for Major Depressive Disorder and Treatment-Resistant Depression
Shots:
- The EPO has granted a patent, EP3927337, to mebufotenin (5-MeO-DMT) and its pharmaceutically acceptable salt for treating major depressive disorder (MDD) along with treatment-resistant forms of MDD, incl. treatment-resistant depression (TRD)
- The patent, effective from Feb 14, 2024, with an expiry date in 2040, covers mebufotenin (5-MeO-DMT) and its salt products through pulmonary inhalation, intravenous, and intranasal routes
- The formulations of the salt include GH001 (inhalation) in a P-IIb study for TRD & two P-IIa PoC studies for bipolar II disorder and a current depressive episode and postpartum depression, GH002 (IV) in a P-I study and GH003 (intranasal) under preclinical development
Ref: GH Research | Image: GH Research
Related News:- MIRA Pharmaceuticals & MIRALOGX Entered into an Exclusive Licensing Agreement for Ketamir-2
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
